FDA Releases Final Label Revision And TA ANDA Amendment Guidances
The FDA Aims To Improve The Development, Review, And Approval Process Of Generic Drugs
While the new guidance on ANDA label revision “provides clear expectations” from the FDA, the revised guidance on amendments to tentatively approved ANDAs is yet to answer questions from AAM.
You may also be interested in...
Under changes in the 2022 appropriations bill, generic drug applications can be approved even if a last-minute labeling update is needed, but sponsors risk product misbranding if the CBE is late.
Both first-cycle approvals and priority assessment improvements have been the subject of questions and criticism as the FDA and industry attempt to boost generic competition.
Approval of Cosette’s first US generic to Rectiv came with a six-month exclusivity as the originator drug had “inadequate generic competition,” but the company has 75 days to enter the market.